4. Stryker Corporation (NYSE:SYK)
Short Percentage of Shares Outstanding: 1.63%
On June 12, BofA lowered its price target on Stryker Corporation (NYSE:SYK) to $380 from $450 while maintaining a Buy rating on the shares. The firm cited a softer healthcare utilization environment highlighted by its services team and adopted a more conservative outlook for 2027 across the medical technology sector. The analyst also incorporated assumptions of increased inflationary pressures and reduced margin expansion potential for medtech companies, leading to lower earnings estimates for larger-cap names with exposure to procedure volumes and cost inflation.
On May 26, Stryker Corporation (NYSE:SYK) announced the European launch of its Pangea Plating System, a comprehensive plating platform designed to address a broad range of fracture patterns. The first clinical procedure using the system in Europe was successfully completed by Professor Alex Trompeter and his team at St. George’s University Hospital in London. The Pangea Plating System consists of non-active implant devices intended to provide temporary stabilization of bones and bone fragments, along with complementary instrumentation that supports implant fit and offers surgeons greater flexibility in fracture fixation procedures involving both upper and lower extremities.
Founded in 1941 and headquartered in Portage, Michigan, Stryker Corporation (NYSE:SYK) is a global medical technology company that designs and manufactures innovative orthopedic implants, surgical equipment, and neurotechnology. The company provides joint replacements, robotic surgical assistance, and spinal technologies that restore mobility and dramatically enhance the quality of life for aging individuals.
